Matsumoto et al evaluated patients with diffuse large B-cell lymphoma (DLBCL). They reported a simple prognostic index that includes anemia. The authors are from Yokohama City University and Kanagawa Cancer Center in Japan.
Patient selection: diffuse large B-cell lymphoma at presentation
Outcome: overall survival (OS) and progression-free survival (PFS) with R-CHOP
Parameters:
(1) anemia
(2) Ann Arbor clinical stage
Anemia was graded using the NCI CTC for Adverse Events
Anemia
Grade
less than lower limit of normal to 10 g/dL
1
8.0 to 9.99 g/dL
2
< 8.0 g/dL
3
transfusion indicated
3
life-threatening
4
Parameter
Finding
Points
anemia
none or grade 1
0
Grade 2 to 4
1
Ann Arbor stage
Stage I or II
0
Stage III or IV
1
where:
• Bone marrow involvement was also a risk factor, but is seen in Stage IV disease.
total score =
= SUM(points for all 2 parameters)
Interpretation:
• minimum score: 0
• maximum score: 2
Total Score
3-Year PFS
3-Year OS
0
89%
95%
1
74%
82%
2
36%
61%
To read more or access our algorithms and calculators, please log in or register.
